Evidence map›Paper›PMID 21858175›Full record

ArticlePloS one2011

Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer.

Kengo Shigehara, Shigeki Yokomuro, Osamu Ishibashi, Yoshiaki Mizuguchi, Yasuo Arima, Yutaka Kawahigashi, Tomohiro Kanda, Ichiro Akagi, Takashi Tajiri, Hiroshi Yoshida and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed, 1 synthesis or guideline pooled it, 151 citations in OpenAlex.

  1. MicroRNA-145 as ideal biomarker for the diagnosis of various carcinomas.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015
    Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Cholangiocarcinoma: The era of liquid biopsy.World journal of gastroenterology · 2025
    Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. MiR-582 Down-Regulates Lissencephaly-1 (Iranian journal of biotechnology · 2022
    Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. [Influence of molecular pathology on oncological surgery of liver and bile duct tumors].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2021
    Review
  19. Article
  20. Review

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Kengo ShigeharaDepartment of Surgery for Organ Function and Biological Regulation, Nippon Medical School, Tokyo, Japan.
Shigeki Yokomuro
Osamu Ishibashi
Yoshiaki Mizuguchi
Yasuo Arima
Yutaka Kawahigashi
Tomohiro Kanda
Ichiro Akagi
Takashi Tajiri
Hiroshi Yoshida
Toshihiro Takizawa
Eiji Uchida
Nippon Medical School · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biliary tract cancer (BTC) is often difficult to diagnose definitively, even through histological examination. MicroRNAs (miRNAs) regulate a variety of physiological processes. In recent years, it has been suggested that profiles for circulating miRNAs, as well as those for tissue miRNAs, have the potential to be used as diagnostic biomarkers for cancer. The aim of this study was to confirm the existence of miRNAs in human bile and to assess their potential as clinical biomarkers for BTC. We sampled bile from patients who underwent biliary drainage for biliary diseases such as BTC and choledocholithiasis. PCR-based miRNA detection and miRNA cloning were performed to identify bile miRNAs. Using high-throughput real-time PCR-based miRNA microarrays, the expression profiles of 667 miRNAs were compared in patients with malignant disease (n = 9) and age-matched patients with the benign disease choledocholithiasis (n = 9). We subsequently characterized bile miRNAs in terms of stability and localization. Through cloning and using PCR methods, we confirmed that miRNAs exist in bile. Differential analysis of bile miRNAs demonstrated that 10 of the 667 miRNAs were significantly more highly expressed in the malignant group than in the benign group at P<0.0005. Setting the specificity threshold to 100% showed that some miRNAs (miR-9, miR-302c*, miR-199a-3p and miR-222*) had a sensitivity level of 88.9%, and receiver-operating characteristic analysis demonstrated that miR-9 and miR-145* could be useful diagnostic markers for BTC. Moreover, we verified the long-term stability of miRNAs in bile, a characteristic that makes them suitable for diagnostic use in clinical settings. We also confirmed that bile miRNAs are localized to the malignant/benign biliary epithelia. These findings suggest that bile miRNAs could be informative biomarkers for hepatobiliary disease and that some miRNAs, particularly miR-9, may be helpful in the diagnosis and clinical management of BTC.

Indexed as

TranscriptomeAdultAgedAged, 80 and overBileBiliary Tract NeoplasmsBiomarkers, TumorCholedocholithiasisFemaleGene Expression ProfilingHumansMaleMicroRNAsMiddle AgedOligonucleotide Array Sequence AnalysisReverse Transcriptase Polymerase Chain ReactionBiomarkers, TumorMicroRNAsMIRN92 microRNA, human

Identifiers

PMID21858175
PMCPMC3157401
OpenAlexW2000465242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.